Nippon India Pharma Fund Growth Return

  • 1M
  • 3M
  • 6M
  • 1Y
  • 3Y
  • 5Y
This Fund:
Sensex:
BankFD:

Showing Funds Performance since Sep 07, 2020

Nippon India Pharma Fund Growth Fund Overview

Min. investment

SIP ₹100 & Lump. ₹5000

AUM (Fund size)

₹9,279 Cr

Lock In Period

N/A

Expense Ratio

1.85

Exit Load

1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units.Nil, thereafter.

Benchmark

BSE Healthcare Total Return

Nippon India Pharma Fund Growth Calculate Returns

You would have got

close_grey_icon
No Data Found
Your Investment Amount
  • 1
  • 2
  • 3
  • 4
  • 5

Growth Review

DurationFund Return(%)Category Average(%)Category Best(%)
1M2.59-0.027.76
6M12.142.3024.90
1Y9.334.8624.15
3Y17.9513.7392.49

Portfolio Analysis

  • Equity: 97.32%
  • Debt: 2.68%
  • Others
As on: 2026-07-31
View allocation % by

1. Sun Pharmaceutical Industries Limited13.31%
2. Lupin Limited7.25%
3. Divi's Laboratories Limited6.52%
4. Cipla Limited6.03%
5. Dr. Reddy's Laboratories Limited5.01%
6. Mankind Pharma Limited3.74%
7. Sai Life Sciences Limited3.62%
8. Ajanta Pharma Limited3.41%
9. MedPlus Health Services Limited2.69%
10. GlaxoSmithKline Pharmaceuticals Limited2.66%
11. IPCA Laboratories Limited2.57%
12. Abbott India Limited2.24%
13. Gland Pharma Limited2.16%
14. Piramal Pharma Limited2.09%
15. Alkem Laboratories Limited2.01%
16. Pfizer Limited1.65%
17. Emcure Pharmaceuticals Limited1.58%
18. Aurobindo Pharma Limited1.54%
19. Syngene International Limited1.46%
20. Sanofi India Limited1.07%
21. Akums Drugs and Pharmaceuticals Limited1.00%
22. Biocon Limited0.92%
23. Anthem Biosciences Limited0.92%
24. AstraZeneca Pharma India Limited0.55%
25. Indoco Remedies Limited0.43%
26. Concord Biotech Limited0.17%

1. Apollo Hospitals Enterprise Limited5.30%
2. Max Healthcare Institute Limited3.15%
3. Thyrocare Technologies Limited2.51%
4. Vijaya Diagnostic Centre Limited2.42%
5. Dr. Lal Path Labs Limited2.05%
6. Narayana Hrudayalaya Limited1.80%
7. Fortis Healthcare Limited1.37%
8. Suraksha Diagnostic Limited1.06%

1. Sanofi Consumer Healthcare India Limited1.06%
No Data Found
No Data Found

About Fund Nippon India Pharma Fund Growth

Nippon India Pharma Fund Growth managed by Nippon India Mutual Fund,is a Healthcare & Pharmascheme with Assets Under Management of ₹9,279 Crore. The fund benchmarks its performance against the BSE Healthcare Total Return while maintaining an expense ratio of 1.85. Under the expert guidance of Sailesh Raj Bhan ,the fund implements a disciplined investment approach aligned with its mandate. The scheme requires a minimum investment of ₹500 for SIP and ₹1,000 for lump sum investments, making it accessible to diverse investor profiles.

Fund Managers

Sailesh Raj Bhan

Mr. Bhan is an MBA with specialization in Finance and CFA. He has over 9 years experience in Equity Securities research and analysis. His pervious experiences include stints with Emkay Share & Stock Broker Pvt. Ltd (2001-2003) where he was Head - Research, Shah & Sequeira Invst. P. Ltd. Analyst (1996-2001), as part of Equity Research, and ICFAI - Securities Research Center (1995- 1996) as an Analyst - Equity Research.

Peer Comparison

Fund NameRatingsAUMExpense Ratio
Baroda BNP Paribas Health and Wellness Fund Growth0519 CR2.78
ITI Pharma and Healthcare Fund Growth0262 CR2.69
Nippon India Pharma Fund Growth49,279 CR1.85
SBI Healthcare Opportunities Fund Growth35,399 CR2
UTI Healthcare Fund Growth31,370 CR2.22
Fund Name1Y3Y
This FundBaroda BNP Paribas Health and Wellness Fund Growth7.17660
This FundITI Pharma and Healthcare Fund Growth9.011563.687
This FundNippon India Pharma Fund Growth9.325564.0754
This FundSBI Healthcare Opportunities Fund Growth17.425385.2747
This FundUTI Healthcare Fund Growth14.354286.9146

Nippon India Pharma Fund Growth FAQs

Nippon India Pharma Fund Growth's fund is managed by experienced SEBI-registered investment fund manager , who implements the fund's strategy through research-backed decisions while adhering to its stated objectives.

The expense ratio of Nippon India Pharma Fund Growth is 1.85. This expense ratio is calculated by dividing the fund's operating expenses by its net assets.

Nippon India Pharma Fund Growth’s fund performance is as follows:
  • 1 Month : 2.59%
  • 6 Months : 12.14%
  • 1 Year : 9.33%
  • 3 Years : 17.95%
Returns of Nippon India Pharma Fund Growth are updated daily based on NAV of ₹ 570.5332 as on Aug 24,2026. Since inception, the return has been 64.08%.

You can invest in Nippon India Pharma Fund Growth through SIP with a minimum of ₹500 monthly or make a lump sum investment of a minimum ₹1,000. Additional purchase minimums vary by scheme.

The fund size (AUM) of Nippon India Pharma Fund Growth is ₹9,279 crore. It changes based on market performance, inflows, and outflows.

You can track your investment in Nippon India Pharma Fund Growth through our website, our Choice FinX mobile app, regular statements, and email updates. Our customer support team is available for queries.